Recurrent Malignant Testicular Germ Cell Tumor Terminated Phase 2 Trials for Deferasirox (DB01609)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01159067Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadSupportive Care